Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pall Opens New Life Sciences CoE in Shanghai

Published: Thursday, October 17, 2013
Last Updated: Thursday, October 17, 2013
Bookmark and Share
New Centre of Excellence extends Pall’s local capabilities in the region.

Pall Corporation has inaugurated the Pall Life Sciences Centre of Excellence (CoE) at its new Zhangjiang site in Shanghai in the People’s Republic of China.

The new Centre of Excellence, which offers biopharmaceutical process solutions, technical and validation support as well as training, extends Pall’s local capabilities for its growing base of life sciences customers in the region.

“This year marks the 20th anniversary of Pall’s expansion into China. The opening of the Shanghai Life Sciences Centre of Excellence is another milestone in Pall’s development in China,” said Larry Kingsley, Chairman and CEO of Pall Corporation.

Kingsley continued, “The new Centre of Excellence not only reinforces our commitment to investing in the region, but also makes it easier for customers in the area to do business with us.”

The new CoE is fully equipped with the most advanced capabilities for process demonstration, testing and validation. Customers also can consult with Pall experts about equipment selection, installation and adjustment.

Integrated with the CoE at the Shanghai facility is a branch office that serves both the company’s Life Sciences and Industrial customers.

More than 200 employees work at the 8,600 m2 Shanghai facility, which provides filtration, separation and purification solutions for a range of industries. These include biopharmaceuticals, medical, food & beverage, process technologies, aerospace and microelectronics.

“China is an important market for Pall and long-term, favorable economic trends give us the confidence to continue development in the potentially high-growth region,” said Hang Gek Low, Vice President of Pall China.

Low continued, “The establishment of the Shanghai CoE enhances our ability to service customers in the area while enabling us to provide dedicated support for Chinese enterprises exploring overseas markets.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pall Corp. Signs Agreement with ATMI
Agreement to acquire ATMI’s LifeSciences business for $185 million.
Friday, December 27, 2013
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!